Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Clinical Trial to Study the Safety and Immunogenicity of a COVAC-2 Booster Dose in Generally Healthy Adults.

NCT05226702 is registered in ClinicalTrials.gov with University of Saskatchewan as lead sponsor.

NCT NCT05226702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05226702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Clinical Trial to Study the Safety and Immunogenicity of a COVAC-2 Booster Dose in Generally Healthy Adults.
Lead sponsor
University of Saskatchewan
Phase
Phase 1
Overall status
Completed
Start date
July 22, 2022
Completion date
November 13, 2023
Enrollment
60 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory syndrome coronavirus 2 (for phase 2 exploratory group), double vaccinated for covid-19 (for phase 1 of the study)